Home efficacy
 

Keywords :   


Tag: efficacy

Transmitter/Receiver optimize wireless power conversion efficacy.

2016-02-24 14:31:04| Industrial Newsroom - All News for Today

Compatible with WPC Qi standard, integrated transmitter (P9240A) and receiver (P9220) chips offer wireless charging solution for electronics demanding up to 15 W output. Power conversion efficiency is >86%. Whereas P9240A suits standalone applications and features proprietary slew rate control, P9220 is designed for products that require high-current charging and incorporates active internal rectifier and output LDO with support for all mainstream communication interface protocols.

Tags: power wireless conversion optimize

 

LED Downlight Retrofits increase commercial lighting efficacy.

2016-02-19 14:31:06| Industrial Newsroom - All News for Today

Designed for hospitality, health care, office, education, and retail environments, ENERGY STAR®-certified DLR Series features 4, 6, 8, and 9 in. configurations with 1,000–5,000 lm outputs. Standard CCTs include 3000K and 4000K, while 2700K, 3500K, and 5000K are options. Flood beam configuration is standard, and spot beam distribution is optional. Offering 100,000 hr operating life, recessed downlight retrofits are compatible with 0–10 V dimmers (120–277 V) and TRIAC dimmers (120 V only).

Tags: increase commercial led lighting

 
 

Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimers Disease

2016-01-28 14:00:26| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimers Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the companys investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimers disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017. Language: English read more

Tags: with safety trial phase

 

Commercial Truck Tires meet durability, fuel efficacy needs.

2016-01-18 14:31:04| Industrial Newsroom - All News for Today

Offered in 6 tread designs and 28 sizes, Uniroyal® tires are available for every tire position and application – long-haul to regional to on-/off-road – and meet needs of dry van, flat bed, construction, and pick-up and delivery vocations. DuraShield® construction employs pyramidal steel belts, insulating belt edge strips, and heavy gauge inner liner to reduce stress, promote endurance, and protect tire casing. SmartWay®-verified Uniroyal RS20™ and LS24™ meet EPA fuel efficiency requirements.

Tags: meet commercial truck fuel

 

Evidence for PrEP efficacy grows, but implementation presents challenges

2015-12-29 04:02:40| Biotech - Topix.net

Pre-exposure prophylaxis was a major topic at the 2015 National HIV Prevention Conference last week in Atlanta. A growing body of evidence continues to confirm that Truvada PrEP is highly effective at preventing HIV infection if taken regularly, both in clinical trials and in real-world clinical use.

Tags: evidence presents implementation challenges

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »